Labiotech.eu

More News! 18 Sep 2017

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […]

September 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]

September 18, 2017 - 1 minutemin - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Inside Labiotech 18 Sep 2017

Press Release: We raised our second financing round to become the largest biotech media 🚀

Happy news to announce this morning: we just closed our second fundraising from new and existing investors 😉👌 It’s a major milestone for the development of Labiotech.eu as it will allow us to continue investing in amazing content, launch new products and grow our revenues. Thanks to the team for their amazing work and for making […]

September 18, 2017 - 3 minutesmins - By Philip Hemme

David Chiswell interview Kymab Antibodies

Interview 18 Sep 2017

David Chiswell: “We are getting close to the best way of making antibodies”

We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […]

September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Sep 2017

How Does it Feel Like to be a Slime Mold in Berlin?

Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […]

September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Sep 2017

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […]

September 15, 2017 - 3 minutesmins - By Alex Dale

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

bayer ginkgo bioworks plant microbiome biotech

News and Trends 15 Sep 2017

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 14 Sep 2017

New Dutch Spin Out will Treat Stroke with RNA Therapy

ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […]

September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 14 Sep 2017

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […]

September 14, 2017 - 2 minutesmins - By Alex Dale

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Press Release: We raised our second financing round to become the largest biotech media 🚀

David Chiswell: “We are getting close to the best way of making antibodies”

How Does it Feel Like to be a Slime Mold in Berlin?

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

New Dutch Spin Out will Treat Stroke with RNA Therapy

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!